Integra Lifesciences (IART) 81.45 $IART Zacks.com

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 12:08 AM

Integra Lifesciences (IART) 81.45 $IART

Zacks.com featured highlights: Beacon Roofing Supply, Core-Mark, HNI, Integra LifeSciences and Post
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 8:30AM CDT
Zacks.com featured highlights: Beacon Roofing Supply, Core-Mark, HNI, Integra LifeSciences and Post
POST: 87.35 (+2.48), IART: 81.45 (+0.59), HNI: 48.15 (+1.08), BECN: 47.73 (+0.71), CORE: 48.34 (+0.97)

5 Medtech Stocks to Watch Out for in 2H16
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 3:30PM CDT
The global Medtech industry is expected to grow at a CAGR of 4.1% to reach a sales value of $477.5 billion in 2020.
IART: 81.45 (+0.59), MASI: 52.33 (+0.34), LNTH: 4.65 (+0.27), LH: 135.30 (+3.33), NUVA: 60.82 (+1.11)

Why the P/S Ratio is My Favorite Valuation Metric
Kevin Matras - Zacks Investment Research - Tue Jul 05, 1:33PM CDT
Why the P/S Ratio is My Favorite Valuation Metric
POST: 87.35 (+2.48), HNI: 48.15 (+1.08), IART: 81.45 (+0.59), BECN: 47.73 (+0.71), CORE: 48.34 (+0.97)

Integra LifeSciences Up 33.7% Since SmarTrend Uptrend Call (IART)
Comtex SmarTrend(R) - Tue Jul 05, 12:57PM CDT
SmarTrend identified an Uptrend for Integra LifeSciences (NASDAQ:IART) on February 22nd, 2016 at $58.86. In approximately 4 months, Integra LifeSciences has returned 33.68% as of today's recent price of $78.68.
IART: 81.45 (+0.59)

Integra LifeSciences at 52-Week High on Solid Q1 Results
Zacks Equity Research - Zacks Investment Research - Mon Jul 04, 7:32AM CDT
Integra Lifesciences (IART)has a market cap of $2.98 billion and a long-term expected earnings growth rate of 11.86%.
IART: 81.45 (+0.59), INVA: 11.64 (+0.26), FCSC: 1.20 (+0.02), ANIP: 56.51 (-1.61)

Integra Life Sciences Forges Ahead with Expansion Plans
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 5:06PM CDT
Integra Life Sciences (IART) recently received FDA approval for its Integra Omnigraft Dermal Regeneration Matrix.
IART: 81.45 (+0.59), HSKA: 43.52 (+2.33), FCSC: 1.20 (+0.02), RTRX: 18.65 (+0.35)

Integra LifeSciences Has Returned 30.3% Since SmarTrend Recommendation (IART)
Comtex SmarTrend(R) - Mon Jun 20, 1:06PM CDT
SmarTrend identified an Uptrend for Integra LifeSciences (NASDAQ:IART) on February 22nd, 2016 at $58.86. In approximately 4 months, Integra LifeSciences has returned 30.30% as of today's recent price of $76.69.
IART: 81.45 (+0.59)

29.5% Return Seen to Date on SmarTrend Integra LifeSciences Call (IART)
Comtex SmarTrend(R) - Fri Jun 10, 1:07PM CDT
SmarTrend identified an Uptrend for Integra LifeSciences (NASDAQ:IART) on February 22nd, 2016 at $58.86. In approximately 4 months, Integra LifeSciences has returned 29.50% as of today's recent price of $76.22.
IART: 81.45 (+0.59)

Integra (IART): Strong Revenue Growth on Global Prospects
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:16AM CDT
On May 31, 2016, we issued an updated research report on Plainsboro, NJ-based Integra LifeSciences Holdings Corporation (IART).
IART: 81.45 (+0.59), ANIP: 56.51 (-1.61), NEO: 9.15 (+0.99), RTRX: 18.65 (+0.35)

Integra LifeSciences Has Returned 23.6% Since SmarTrend Recommendation (IART)
Comtex SmarTrend(R) - Thu May 26, 1:24PM CDT
SmarTrend identified an Uptrend for Integra LifeSciences (NASDAQ:IART) on February 22nd, 2016 at $58.86. In approximately 3 months, Integra LifeSciences has returned 23.61% as of today's recent price of $72.75.
IART: 81.45 (+0.59)

Integra LifeSciences to Present at the Jefferies 2016 Healthcare Conference in June 2016
GlobeNewswire - Wed May 25, 3:05PM CDT
Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it will present at the following conferences in June:
IART: 81.45 (+0.59), IARTV: 65.00 (-37.45)

Integra Unveils Fin-Lock Glenoid, Boosts Shoulder Arthroplasty
Zacks Equity Research - Zacks Investment Research - Tue May 24, 7:22AM CDT
Integra LifeSciences Holdings Corporation (IART) recently launched Integra Fin-Lock Glenoid.
IART: 81.45 (+0.59), HSKA: 43.52 (+2.33), ANIP: 56.51 (-1.61), NEO: 9.15 (+0.99)

Integra LifeSciences launches Integra(R) Fin-Lock(TM) Glenoid for the Titan(TM) Modular Shoulder System
GlobeNewswire - Mon May 23, 7:30AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced the launch of the Integra(R) Fin-Lock(TM) Glenoid. This addition to the Titan(TM) Modular Shoulder System increases the glenoid offerings to include features intended to help maximize long-term fixation and implant longevity.
IART: 81.45 (+0.59), IARTV: 65.00 (-37.45)

Shares of IART Up 22.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu May 19, 1:05AM CDT
SmarTrend identified an Uptrend for Integra LifeSciences (NASDAQ:IART) on February 22nd, 2016 at $58.86. In approximately 3 months, Integra LifeSciences has returned 22.10% as of today's recent price of $71.86.
IART: 81.45 (+0.59)

Uptrend Call Working As Integra LifeSciences Stock Rises 24.3% (IART)
Comtex SmarTrend(R) - Wed May 11, 1:17PM CDT
SmarTrend identified an Uptrend for Integra LifeSciences (NASDAQ:IART) on February 22nd, 2016 at $58.86. In approximately 3 months, Integra LifeSciences has returned 24.27% as of today's recent price of $73.14.
IART: 81.45 (+0.59)

Integra LifeSciences Receives FDA Approval for Integra(R) Omnigraft(TM) Dermal Regeneration Matrix, Clearing the Way for Commercial Release
GlobeNewswire - Wed May 11, 7:30AM CDT
Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) for the packaging of its new product, Integra(R) Omnigraft(TM) Dermal Regeneration Matrix, which clears the way for its commercial release. The product's unique packaging is designed for ease of handling and application in the outpatient wound care setting.
IART: 81.45 (+0.59), IARTV: 65.00 (-37.45)

Integra LifeSciences to Present at the Bank of America Merrill Lynch 2016 Health Care Conference and the UBS Global Healthcare Conference in May 2016
GlobeNewswire - Tue May 03, 3:15PM CDT
Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it will present at the following conferences in May:
IART: 81.45 (+0.59), IARTV: 65.00 (-37.45)

Integra (IART) Beats on Q1 Earnings, Grows Organically
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:36PM CDT
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share (EPS) of 74 cents in the first quarter of 2016.
IART: 81.45 (+0.59), ANIP: 56.51 (-1.61), ANIK: 53.30 (+0.94), ALQA: 1.19 (-0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UCB's Endowment Marks New Era in Medicine Evaluation

Stepping into a New Chapter for Medicine Evaluation UCB's latest move smacks of a strategic vision that's not just about immediate returns—it's a long game in pharmacoepidemiology. You don't see investors lining up for this news, but this chair at Brigham and Women's is bigger than it looks. By establishing the Emmanuel Janssen Endowed Chair, UCB is underpinning the...

Italian Excellence: NYC Celebrates Innovators and Icons

The Fusion of Italian Artistry and Innovation Imagine blending business savvy with a touch of culture and ethics. That's the spirit of the 9th Business Care International Award, which is gearing up to hit New York City's grand stage come November 18-19. This ain't just about pats on the back; it's a recognition of those who push Italian excellence across oceans and into...

Hims & Hers Faces Securities Lawsuit Amid Stock Dive

Hims & Hers Takes a Hit Right out of the gate, we're seeing Hims & Hers Health, Inc. (NYSE:HIMS) embroiled in a securities class action, thanks to some good old-fashioned alleged corporate shenanigans. It's one of those times where you'd cock an eyebrow and say, "What in the world were they thinking?" The FTC has slapped them with accusations of misleading privacy claims...

Better Home & Finance Faces Class Action: What's Next?

Stock Hit and Legal Drama Panic set in when Better Home & Finance Holding Company took a 28.5% nosedive after spilling some less-than-sweet news. Their promise of hitting a billion in monthly loans? Stuck in limbo as borrower trepidation reared its ugly head amidst rising rates. Investors felt the heat, watching shares skydive $12.17, landing them at a bruised $30.52. A...

Navigating Home Sales: Expert Insights from Jodi Kallus

Preparing for the Real Estate Rollercoaster Getting ready to sell your home? Let's cut through the noise and get right into the nitty-gritty with Jodi Kallus, a seasoned real estate pro with Summit Realtors. The first step ain't just about slapping a ‘For Sale’ sign on your front lawn. It's about laying down a plan that's as solid as the foundation of the house you're...

Ensign Lawsuit Brews: Investor Stakes High by Dec. 7

Ensign's Alleged Missteps Uncovered Man, grabbing headlines in the finance world often feels like catching a whirlwind, and yet, here we are with Ensign Group's latest debacle. This isn't some run-of-the-mill story we're sifting through. It's a class action lawsuit with teeth, aiming to rope in investors who played ball during a hefty stretch running from February 10,...

Patriot Fund Gala Celebrates Veterans and America's 250th

Celebrating Service and Patriotism in Philadelphia The Patriot Fund is gearing up for its 11th Annual Gala, a night dedicated to honoring the veterans who have sacrificed so much for this nation. Set against the historic backdrop of Philadelphia, the gala coincides with America's 250th anniversary—couldn't have picked a better time or place for such an event. It’s not...

Netcapital's Revenue Fraud Scandal Hits Investor Confidence

The Rise and Fall of Netcapital: A Troubling Drop Netcapital Inc. (NASDAQ: NCPL) has found itself in hot water with investors after revelations of a wild scheme to fluff up its revenue figures. It’s like watching a house of cards crumble — and investors are left holding the bag. From December 15, 2021, through September 3, 2026, a slew of misinformation allegedly...

Likang's Bold Move: Cancer Immunotherapy at AD Summit

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Millrose Faces Securities Fraud Suit Amidst Decline

Dark Clouds Over Millrose Properties Holy smokes, folks, if Millrose Properties thought it could skirt under the radar, they were dead wrong. The curtain's been peeled back, and what do we see? A mess of securities fraud allegations and financial hiccups that’s driving its shareholders mad. October wasn’t too friendly—Hunterbrook Media dropped a bombshell revealing...